KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Equity Income: 2018-2020

Historic Equity Income for Arbutus Biopharma (ABUS) over the last 3 years, with Dec 2020 value amounting to -$2.5 million.

  • Arbutus Biopharma's Equity Income rose 27.53% to -$2.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$20.4 million, marking a year-over-year decrease of 43.56%. This contributed to the annual value of -$2.5 million for FY2020, which is 88.70% up from last year.
  • As of FY2020, Arbutus Biopharma's Equity Income stood at -$2.5 million, which was up 88.70% from -$22.5 million recorded in FY2019.
  • Arbutus Biopharma's Equity Income's 5-year high stood at -$2.5 million during FY2020, with a 5-year trough of -$22.5 million in FY2019.
  • In the last 3 years, Arbutus Biopharma's Equity Income had a median value of -$5.6 million in 2018 and averaged -$10.2 million.
  • Its Equity Income has fluctuated over the past 5 years, first slumped by 304.93% in 2019, then spiked by 88.70% in 2020.
  • Over the past 3 years, Arbutus Biopharma's Equity Income (Yearly) stood at -$5.6 million in 2018, then plummeted by 304.93% to -$22.5 million in 2019, then soared by 88.70% to -$2.5 million in 2020.